<DOC>
	<DOCNO>NCT01376362</DOCNO>
	<brief_summary>The objective study investigate safety efficacy ocular instillation interferon gamma-1b potential treatment cystoid macular edema ( CME ) secondary uveitis .</brief_summary>
	<brief_title>Topical Interferon Gamma Macular Edema Secondary Uveitis</brief_title>
	<detailed_description>Objective : Information gather NEI laboratory suggest cystoid macular edema ( CME ) cause disequilibrium JakStat mTor signal transduction pathway retinal pigment epithelium ( RPE ) . We wish investigate whether stimulate JakStat pathway topically apply interferon gamma-1b therapeutic intervention treatment CME secondary uveitis . The objective study investigate safety efficacy ocular instillation interferon gamma-1b potential treatment CME secondary uveitis . Study Population : Five participant CME evidence OCT ( &gt; 275 micron central macular thickness and/or loss foveal contour ) secondary uveitis receive topical ocular instillation interferon gamma-1b . Up seven participant may enrol order obtain five participant include analysis participant withdraw prior receive interferon gamma-1b . Design : This Phase I/II , non-randomized , prospective , uncontrolled , single-center study involve instill four drop interferon gamma-1b ( approximately 30 μg ) topically cornea study eye four time day one week measure potential response optical coherence tomography ( OCT ) . Outcome Measures : The primary outcome change excess central macular thickening measure OCT response interferon gamma-1b . Treatment success define 25 % decrease excess central macular thicken Week 1 compare baseline . Secondary efficacy outcome include change macular volume measure OCT , visual acuity , intraocular pressure intraocular inflammation grade upon slit lamp examination . Secondary safety outcome include ocular surface irritation assess fluorescein stain cornea conjunctiva ass toxicity , number severity systemic ocular toxicity , number adverse event proportion participant visual loss ≥ 15 Early Treatment Diabetic Retinopathy Study ( ETDRS ) letter .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Uveitis , Anterior</mesh_term>
	<mesh_term>Iridocyclitis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>Inclusion Criteria 1 . Participant must 18 year age old . 2 . Participant must understand sign protocol 's informed consent document . 3 . Participant diagnosis CME ( central thickness &gt; 275 micron OCT and/or disruption foveal contour ) secondary uveitis least one eye ( study eye ) . 4 . Participant willing comply study procedure expect able return study visit . 5 . Participant visual acuity 20/400 good study eye . 6 . Female participant childbearing potential must pregnant breastfeeding . 7 . Both female participant childbearing potential male participant able father child must agree practice two acceptable form contraception study six week follow last administration investigational product . Acceptable method contraception include hormonal contraception ( i.e. , birth control pill , inject hormone dermal patch vaginal ring ) , intrauterine device , barrier method spermicide ( diaphragm spermicide , condom spermicide ) surgical sterilization ( hysterectomy , tubal ligation vasectomy ) . Exclusion Criteria 1 . Participant unable tolerate ocular instillation follow study procedure . 2 . Participant significant active infection ( infection require treatment determine medical team ) principal investigator 's best medical judgment would preclude participation . 3 . Participant multiple sclerosis ( MS ) , interferon gamma may cause MS exacerbation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Cystoid Macular Edema</keyword>
	<keyword>Intermediate Uveitis</keyword>
	<keyword>Uveitis</keyword>
	<keyword>OCT</keyword>
	<keyword>Interferon-Gamma ( IFN-Gamma )</keyword>
</DOC>